Developer docs
API playgroundTry for free, no card

Search company profiles

Alembic

Full company profile

uuid003a19h

Namestring
Alembic
Legal namestring
Alembic Limited
Company typeenum
Public
Founded yearint
1907
Descriptiontext

Alembic Limited is a Vadodara-headquartered Indian public limited company incorporated in 1907 (CIN: L26100GJ1907PLC000033), listed on BSE (506235) and NSE (ALEMBICLTD). It operates as a diversified holding-style conglomerate with three distinct business segments: Pharmaceuticals (manufacturing and marketing of fermentation and chemistry-based Active Pharmaceutical Ingredients with R&D activity at Vadodara), Real Estate (construction of residential and commercial projects, project management, marketing consultancy, and commercial property leasing — operated through wholly-owned subsidiary Alembic City Limited), and Power Assets (co-generation plants totaling 11 MW plus four windmills totaling 5 MW).

The company's pharmaceutical segment is its core revenue contributor, producing APIs for the pharmaceutical industry via direct B2B sales with a domestic-India geographic scope. Manufacturing and R&D operations are concentrated at the Vadodara facility on Alembic Road. Capital intensity is a defining feature: 16 MW of captive power capacity supports manufacturing economics, and the firm also leases commercial real estate to multiple tenants.

Revenue generation is split across the three segments with no disclosed pricing transparency. Recent quarterly performance shows Rs 60.04 crore in Q4 FY26 (revenue) and Rs 74.34 crore in Q3 FY26, with profitability under pressure (Q4 FY26 consolidated net profit of Rs 9.61 crore, down 59.53% YoY). The Amin family, through Nirayu Limited (59.27% stake), controls 67.09% of equity via promoter holdings, leaving 32.91% with public shareholders including SBI Small Cap Fund (5.84%). Alembic Limited is distinct from its associated company Alembic Pharmaceuticals Limited, in which it holds a minority stake — a structural point that affects how the entity's standalone economics should be read versus group-wide financials.

Short descriptiontext

Alembic Limited is a Vadodara, India-based conglomerate founded in 1907 that manufactures fermentation and chemistry-based Active Pharmaceutical Ingredients, develops residential and commercial real estate via subsidiary Alembic City Limited, and operates 16 MW of co-generation and wind power capacity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBarry, United Kingdom
HQ citystring
Barry
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, API manufacturing, pharmaceutical formulations, real estate development, power generation
Industry2 codes
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Industrial Organic Chemicals2860
Product category
Pharmaceutical API Manufacturing
Social media profiles1 record
Revenue model3 records
1Pharmaceuticals (API)
TypeOne Time License
Description

Manufacturing and marketing of fermentation and chemistry based Active Pharmaceuticals Ingredients (API) with Research and Development activities at Vadodara facility.

alembiclimited.com
2Real Estate
TypeOne Time License
Description

Construction of residential and commercial real estate projects, project management and marketing consultancy. The company also gives commercial properties on lease to various tenants.

alembiclimited.com
3Power Generation
TypeOne Time License
Description

Power generation through co-generation plants (11 MW total) and wind power (4 windmills of 5 MW total capacity).

alembiclimited.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alembic Limited manufactures and markets fermentation and chemistry-based Active Pharmaceutical Ingredients (APIs) supported by in-house R&D at its Vadodara facility, with a diversified portfolio that also includes construction of residential and commercial real estate projects (plus leasing of commercial properties) and power generation through co-generation (11 MW) and wind power (5 MW across four windmills).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Alembic Limited is a diversified Indian conglomerate with three distinct business segments operating as separate product lines rather than a unified platform. The company's core operations include: (1) Pharmaceuticals - manufacturing and marketing of fermentation and chemistry-based Active Pharmaceuticals Ingredients (API) with R&D capabilities at Vadodara; (2) Real Estate - construction of residential and commercial projects with property management and marketing consultancy services, plus commercial property leasing; and (3) Power Assets - co-generation plants (11 MW total) and wind power generation through 4 windmills (5 MW total). The company does not offer a software platform or integrated product suite.

Product and service4 records
1Pharmaceuticals (Active Pharmaceutical Ingredients)
CategoryPharmaceutical API Manufacturing
2Real Estate (Residential and Commercial)
CategoryReal Estate Development and Leasing
3Co-Generation Power
CategoryPower Generation
4Wind Power
CategoryPower Generation
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-18
Description

Bharat Taxi partnered with Alembic Foundation's #ForHerWithHer initiative to provide pink auto-rickshaw drivers access to a larger customer base, digital payment systems, and improved safety features. The platform operates a zero-commission model.

2MUFG Intime India Private Limited
Strategic tierCoreTypeOthers
Description

Registrar and Transfer Agent for Alembic Limited. Located at 'Geetakunj', 1 Bhakti Nagar Society, Behind ABS Tower, Old Padra Road, Vadodara – 390 015, Gujarat.

alembiclimited.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Indian pharmaceutical company combining API manufacturing with branded and generic finished formulations, particularly in oncology and niche therapeutic areas. Comparable given its API+formulations integrated model serving regulated and emerging markets.

TypeDirect peer
Description

Indian contract development and manufacturing organization (CDMO) focused on APIs and intermediates with chemistry-focused capabilities. Comparable to Alembic's chemistry-based API manufacturing model and similar mid-tier positioning in global API supply.

TypeDirect peer
Description

Indian API and intermediates manufacturer with strong chemistry-based synthesis capabilities serving generic and antiretroviral markets. Directly comparable as a mid-scale Indian API specialist competing in similar therapeutic categories and chemistry platforms.

TypeDirect peer
Description

Indian pure-play API manufacturer focused on fermentation and chemistry-based APIs for global generics and custom synthesis. Most directly comparable to Alembic Limited given shared fermentation/chemistry capabilities and API-focused customer base.

TypeDirect peer
Description

Indian pharmaceutical manufacturer with significant API and intermediate capabilities feeding its formulations business. Comparable as a vertically integrated API+formulations Indian peer with similar fermentation/chemistry production.

TypeBroad incumbent
Description

Large Indian integrated pharmaceutical company with significant API manufacturing across fermentation and chemistry platforms serving global regulated markets. Comparable due to overlapping API manufacturing model, though much larger in scale and broader in finished dosage forms.

TypeEmerging player
Description

Indian API CDMO offering contract development and manufacturing services for global pharma and biotech customers. Comparable given shared API manufacturing focus and India-based cost structure serving regulated market customers.

TypeDirect peer
Description

Indian API and contract research services company focused on central nervous system and other therapeutic categories. Comparable as a mid-tier Indian API manufacturer with chemistry-based capabilities targeting global pharma clients.

TypeEmerging player
Description

Privately-held Indian pharmaceutical manufacturer with API production capabilities and growing formulations business. Comparable as another India-based API player with chemistry manufacturing serving global generic markets.

TypeBroad incumbent
Description

Indian-headquartered global pharmaceutical company with significant API and contract manufacturing capabilities across multiple therapeutic areas. Comparable due to API manufacturing overlap and global customer reach, though broader in finished dosage offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alembic

Pharmaceutical API Manufacturingalembiclimited.com

Alembic Limited is a Vadodara, India-based conglomerate founded in 1907 that manufactures fermentation and chemistry-based Active Pharmaceutical Ingredients, develops residential and commercial real estate via subsidiary Alembic City Limited, and operates 16 MW of co-generation and wind power capacity.

What Alembic does

Alembic Limited is a Vadodara-headquartered Indian public limited company incorporated in 1907 (CIN: L26100GJ1907PLC000033), listed on BSE (506235) and NSE (ALEMBICLTD). It operates as a diversified holding-style conglomerate with three distinct business segments: Pharmaceuticals (manufacturing and marketing of fermentation and chemistry-based Active Pharmaceutical Ingredients with R&D activity at Vadodara), Real Estate (construction of residential and commercial projects, project management, marketing consultancy, and commercial property leasing — operated through wholly-owned subsidiary Alembic City Limited), and Power Assets (co-generation plants totaling 11 MW plus four windmills totaling 5 MW).

The company's pharmaceutical segment is its core revenue contributor, producing APIs for the pharmaceutical industry via direct B2B sales with a domestic-India geographic scope. Manufacturing and R&D operations are concentrated at the Vadodara facility on Alembic Road. Capital intensity is a defining feature: 16 MW of captive power capacity supports manufacturing economics, and the firm also leases commercial real estate to multiple tenants.

Revenue generation is split across the three segments with no disclosed pricing transparency. Recent quarterly performance shows Rs 60.04 crore in Q4 FY26 (revenue) and Rs 74.34 crore in Q3 FY26, with profitability under pressure (Q4 FY26 consolidated net profit of Rs 9.61 crore, down 59.53% YoY). The Amin family, through Nirayu Limited (59.27% stake), controls 67.09% of equity via promoter holdings, leaving 32.91% with public shareholders including SBI Small Cap Fund (5.84%). Alembic Limited is distinct from its associated company Alembic Pharmaceuticals Limited, in which it holds a minority stake — a structural point that affects how the entity's standalone economics should be read versus group-wide financials.

Alembic firmographics

Firmographics
Name
Alembic
Legal name
Alembic Limited
Website
https://alembiclimited.com
Company type
Public
Founded year
1907
Operating status
Operating
Headcount range
51–100 employees
Short description
Alembic Limited is a Vadodara, India-based conglomerate founded in 1907 that manufactures fermentation and chemistry-based Active Pharmaceutical Ingredients, develops residential and commercial real estate via subsidiary Alembic City Limited, and operates 16 MW of co-generation and wind power capacity.
Ownership category
akta.pro rank

Alembic industry classification

Industry
Product category
Pharmaceutical API Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)
akta.pro industry
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Active pharmaceutical ingredients
  • API manufacturing
  • Pharmaceutical formulations
  • Real estate development
  • Power generation

Where Alembic is headquartered

Location

Headquarters

HQ city
Barry
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Alembic business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceuticals (API): Manufacturing and marketing of fermentation and chemistry based Active Pharmaceuticals Ingredients (API) with Research and Development activities at Vadodara facility.
  2. Real Estate: Construction of residential and commercial real estate projects, project management and marketing consultancy. The company also gives commercial properties on lease to various tenants.
  3. Power Generation: Power generation through co-generation plants (11 MW total) and wind power (4 windmills of 5 MW total capacity).

Distribution channels1 record

Alembic product offering

Product offering

Core offering

Alembic Limited manufactures and markets fermentation and chemistry-based Active Pharmaceutical Ingredients (APIs) supported by in-house R&D at its Vadodara facility, with a diversified portfolio that also includes construction of residential and commercial real estate projects (plus leasing of commercial properties) and power generation through co-generation (11 MW) and wind power (5 MW across four windmills).

Product overview

Alembic Limited is a diversified Indian conglomerate with three distinct business segments operating as separate product lines rather than a unified platform. The company's core operations include: (1) Pharmaceuticals - manufacturing and marketing of fermentation and chemistry-based Active Pharmaceuticals Ingredients (API) with R&D capabilities at Vadodara; (2) Real Estate - construction of residential and commercial projects with property management and marketing consultancy services, plus commercial property leasing; and (3) Power Assets - co-generation plants (11 MW total) and wind power generation through 4 windmills (5 MW total). The company does not offer a software platform or integrated product suite.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceuticals (Active Pharmaceutical Ingredients)
  • Real Estate (Residential and Commercial)
  • Co-Generation Power
  • Wind Power

Companies that use Alembic

Customer profile

Segments1 record

Ideal customer profiles2 records

Alembic technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Alembic partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Bharat TaximinorGTM or Marketing Partner · 18 April 2026Bharat Taxi partnered with Alembic Foundation's #ForHerWithHer initiative to provide pink auto-rickshaw drivers access to a larger customer base, digital payment systems, and improved safety features. The platform operates a zero-commission model.
  • MUFG Intime India Private LimitedcoreOthersRegistrar and Transfer Agent for Alembic Limited. Located at 'Geetakunj', 1 Bhakti Nagar Society, Behind ABS Tower, Old Padra Road, Vadodara – 390 015, Gujarat.

Scale indicators5 records

Recent moves9 records

Expansion highlights4 records

Alembic competitors and assessment

Company assessment

Broad incumbents

  • NATCO Pharma: Indian pharmaceutical company combining API manufacturing with branded and generic finished formulations, particularly in oncology and niche therapeutic areas. Comparable given its API+formulations integrated model serving regulated and emerging markets.
  • Aurobindo Pharma: Large Indian integrated pharmaceutical company with significant API manufacturing across fermentation and chemistry platforms serving global regulated markets. Comparable due to overlapping API manufacturing model, though much larger in scale and broader in finished dosage forms.
  • Piramal Pharma: Indian-headquartered global pharmaceutical company with significant API and contract manufacturing capabilities across multiple therapeutic areas. Comparable due to API manufacturing overlap and global customer reach, though broader in finished dosage offerings.

Direct peers

  • Neuland Laboratories: Indian contract development and manufacturing organization (CDMO) focused on APIs and intermediates with chemistry-focused capabilities. Comparable to Alembic's chemistry-based API manufacturing model and similar mid-tier positioning in global API supply.
  • Laurus Labs: Indian API and intermediates manufacturer with strong chemistry-based synthesis capabilities serving generic and antiretroviral markets. Directly comparable as a mid-scale Indian API specialist competing in similar therapeutic categories and chemistry platforms.
  • Divi's Laboratories: Indian pure-play API manufacturer focused on fermentation and chemistry-based APIs for global generics and custom synthesis. Most directly comparable to Alembic Limited given shared fermentation/chemistry capabilities and API-focused customer base.
  • Granules India: Indian pharmaceutical manufacturer with significant API and intermediate capabilities feeding its formulations business. Comparable as a vertically integrated API+formulations Indian peer with similar fermentation/chemistry production.
  • Suven Pharmaceuticals: Indian API and contract research services company focused on central nervous system and other therapeutic categories. Comparable as a mid-tier Indian API manufacturer with chemistry-based capabilities targeting global pharma clients.

Emerging players

  • Sai Life Sciences: Indian API CDMO offering contract development and manufacturing services for global pharma and biotech customers. Comparable given shared API manufacturing focus and India-based cost structure serving regulated market customers.
  • MSN Laboratories: Privately-held Indian pharmaceutical manufacturer with API production capabilities and growing formulations business. Comparable as another India-based API player with chemistry manufacturing serving global generic markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Alembic social profiles

Digital presence

Alembic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alembic leadership team

Management profile

Number of profiles

Profiles10 records

Alembic subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Alembic funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alembic M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alembic

What does Alembic do?

Alembic Limited manufactures and markets fermentation and chemistry-based Active Pharmaceutical Ingredients (APIs) supported by in-house R&D at its Vadodara facility, with a diversified portfolio that also includes construction of residential and commercial real estate projects (plus leasing of commercial properties) and power generation through co-generation (11 MW) and wind power (5 MW across four windmills).

Is Alembic a public or private company?

Alembic is a public company. It is classified as public and is currently operating.

When was Alembic founded?

Alembic was founded in 1907. It employs 51 to 100 people.

Where is Alembic based?

Alembic is headquartered in Barry, United Kingdom, in the Europe region.

How does Alembic make money?

Three revenue lines are on record. Pharmaceuticals (API) is the primary driver. The others are real Estate and power Generation.

Who are Alembic's main competitors?

Broad incumbents on record are NATCO Pharma, Aurobindo Pharma and Piramal Pharma. Direct peers are Neuland Laboratories, Laurus Labs, Divi's Laboratories, Granules India and Suven Pharmaceuticals. Emerging players are Sai Life Sciences and MSN Laboratories.

Does Alembic have an API?

No public API is recorded for Alembic.

What industry is Alembic in?

Alembic's product category is Pharmaceutical API Manufacturing. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 3254 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXAlembic Limited shareholders approve FY26 results, dividend with near-unanimous supportAlembic Limited's 119th Annual General Meeting concluded with shareholders providing near-unanimous approval for the FY26 financial statements, dividend declaration, and key governance matters. Voting results showed 100% support for the adoption of financial statements and dividend-related resolutions, with minimal dissent recorded on executive compensation and director appointments. The meeting marks a routine corporate governance exercise with no material disputes or concerns raised by the shareholder body.The Times of IndiaAlembic to mark 119th foundation day with CSR initiatives | Vadodara News - The Times of IndiaAlembic Group will mark its 119th foundation day on Thursday with CSR activities including planting 11,900 saplings along the Chhani canal for environmental conservation and distributing 11,900 nutritious meals to children at government schools and NGO beneficiaries in Vadodara. A blood donation drive is also planned as part of the celebrations. The initiatives are being coordinated through the Alembic CSR Foundation under trustee Mallika Chiraju Amin.MintTrump's tariff policy: Abbott India, Ajanta Pharma to Alembic — pharma stocks crash up to 4% | Stock Market NewsUS President Donald Trump announced a phased tariff plan on imported generic medicines on July 24, 2026, causing Indian pharmaceutical stocks to decline as much as 4%, with Abbott India falling 3.69% and other pharma companies including Ajanta Pharma, Alembic, Akums Drugs & Pharmaceuticals, Acutaas Chemicals, Aarti Drugs, and Artemis Medicare Services also trading lower. Under the proposed policy, generic drug imports will face zero tariffs for two years before escalating to 100% from August 2028 and 200% from August 2029, with the aim of encouraging pharmaceutical companies to shift manufacturing to the United States. Indian drugmakers account for nearly 47% of the US generic medicines market, and analysts expect continued negative sentiment in pharma stocks until greater policy clarity emerges.In VivoFDA Nod Deepens Looming Challenge To Lynparza FranchiseNatco’s generic olaparib tablets received tentative FDA approval, bringing the product closer to market but facing delays due to litigations and patent issues. Alembic is set to distribute the approved product in the US.ScanXAlembic Limited to hold 119th AGM on August 11, 2026Alembic Limited will hold its 119th Annual General Meeting virtually on August 11, 2026, to adopt FY26 financial results and declare a dividend. The meeting includes a special resolution to pay ₹210 Lakhs commission to Mr. Udit Amin and ratify cost auditor fees, with August 4, 2026 set as the record date for dividend eligibility.Business StandardAlembic slides as Q4 PAT tanks 60% YoY to Rs 10 crAlembic's consolidated net profit dropped 59.53% to Rs 9.61 crore in Q4 FY26, compared to Rs 23.75 crore in Q4 FY25, as the company's total expenses surged 20.42% YoY to Rs 43.74 crore. Revenue from operations marginally declined by 0.38% YoY to Rs 60.04 crore in the same period. The board recommended a dividend of Rs 2.40 per equity share for FY26 despite the profitability decline.ET NOWAlembic Pharma Q4 Results FY 2026: Rs 12 per share dividend announced in quarterly earnings - Profit up 32% YoY - MarketsAlembic Pharma announced its Q4 results for the financial year 2025-26, reporting a profit increase of 32% year-over-year. The company declared a dividend of Rs 12 per share as part of its quarterly earnings. The article contains only headline figures without detailed financial breakdowns.The Times of IndiaAlembic Campus Road thrown open to trafficUnrestricted traffic movement was recently allowed on a road passing through Alembic Ltd's campus in Vadodara, following verification that part of it is a public path. The gates and barricades that caused inconvenience were removed, easing congestion at Genda Circle during peak hours.The Times of IndiaIndia strategic launchpad for next wave of obesity care - The Economic TimesIndia is emerging as a pivotal hub for semaglutide active pharmaceutical ingredient (API) manufacturing, with leading pharmaceutical firms building significant production capacity to tap the booming global market for obesity and diabetes treatments, according to IQVIA. Companies including Aurobindo, Dr Reddy's, Lupin, Alembic, and Biocon are investing in kilo-scale peptide synthesis labs and dedicated API production lines to capture GLP-1 demand when patents lose exclusivity. The global anti-obesity drug market is projected to reach $100-200 billion by 2030, with India positioned as a strategic launchpad for emerging and self-pay markets.